SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (1659)11/8/1999 9:13:00 PM
From: WTDEC  Read Replies (1) | Respond to of 2173
 
Monday November 8, 5:15 pm Eastern Time
Company Press Release
SOURCE: Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals Reports Positive Results For SYMLIN In US Type 1 Diabetes Study
Mid-2000 Regulatory Submissions on Schedule
SAN DIEGO, Nov. 8 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - news) today announced that its lead diabetes drug candidate, SYMLIN(TM) (pramlintide acetate), produced a statistically significant lowering of the primary glucose control endpoint in a one-year, pivotal Phase 3 clinical study in type 1 diabetes. The Company has now completed its planned pivotal clinical activities for SYMLIN and is preparing mid-2000 regulatory submissions for type 1 and insulin-using type 2 diabetes in the US and Europe.



To: celeryroot.com who wrote (1659)11/9/1999 5:55:00 PM
From: Edward Boghosian  Read Replies (2) | Respond to of 2173
 
This is good but the phrase: "statistically significant decrease" is not the same as significant decrease. I would like to see whole numbers instead of 0.7 and 0.4. Whatever, it does seem positive as judged by the jump. I hope it all works out.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News